

Date of submission: 25th January 2024

To, The Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code – 539551	To, The Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051 NSE Symbol- NH
---	---

Dear Sir/Madam,

Sub: Intimation of incorporation of a Research oriented entity

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) we hereby inform that the Company has incorporated an entity under Section 8 of the Companies Act, 2013 named “Narayana Clinical Research India Foundation” on 25th January 2024.

The details as required under Regulation 30 of the Listing Regulations read with SEBI circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015 are enclosed herewith as Annexure.

The aforesaid information is being made available on the Company’s website i.e. <https://www.narayanahealth.org/>

Kindly take the same on record.

Thanking you

Yours faithfully,
For **Narayana Hrudayalaya Limited**

Sridhar S
Group Company Secretary, Legal & Compliance Officer

Encl: as above

Annexure

Details of the entity pursuant to SEBI circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sl. No.	Particulars	Description
1	Name of the target entity, details in brief such as size, turnover etc.	Name: NARAYANA CLINICAL RESEARCH INDIA FOUNDATION CIN: U86201KA2024NPL183911 Authorised Capital, Paid Up Capital and Turnover: Not Applicable as it is a Section 8 Company limited by guarantee without capital.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	N.A.
3	Industry to which the entity being acquired belongs	Clinical Research
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The entity is incorporated mainly to promote research activities in medical, clinical and healthcare fields on non-profit basis working with government and non-government organizations and all sections of society.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable
7	Nature of consideration - whether cash consideration or share swap and details of the same	The Company incorporated with Guarantee and not having a share capital
8	Cost of acquisition or the price at which the shares are acquired	The Company incorporated with Guarantee and not having a share capital

Sl. No.	Particulars	Description
9	Percentage of shareholding / control acquired and / or number of shares acquired	The Company incorporated with Guarantee and not having a share capital with the Company liable to bear any liability arising whenever the entity is dissolved.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Narayana Clinical Research India Foundation is incorporated on 25th January 2024 under the Companies Act, 2013 under the CIN: U86201KA2024NPL183911 with registered office situated in the State of Karnataka.</p> <p>Its main object is to promote the healthcare and research activities on Non-profit basis working with government and nongovernment organizations and all sections of society.</p>